Literature DB >> 24957265

IL-9 and its receptor are predominantly involved in the pathogenesis of UC.

Nancy Nalleweg1, Mircea Teodor Chiriac2, Eva Podstawa1, Christian Lehmann3, Tilman T Rau4, Raja Atreya1, Ekaterina Krauss1, Gheorghe Hundorfean1, Stefan Fichtner-Feigl5, Arndt Hartmann4, Christoph Becker1, Jonas Mudter6.   

Abstract

OBJECTIVE: Several pathogenic roles attributed over the past two decades to either T helper (Th)1 or Th2 cells are increasingly becoming associated with interleukin (IL)-17 and most recently IL-9 signalling. However, the implication of IL-9 in IBD has not been addressed so far.
DESIGN: We investigated the expression of IL-9 and IL-9R by using peripheral blood, biopsies and surgical samples. We addressed the functional role of IL-9 signalling by analysis of downstream effector proteins. Using Caco-2 cell monolayers we followed the effect of IL-9 on wound healing.
RESULTS: IL-9 mRNA expression was significantly increased in inflamed samples from patients with UC as compared with controls. CD3(+) T cells were major IL-9-expressing cells and some polymorphonuclear leucocytes (PMN) also expressed IL-9. IL-9 was co-localised with the key Th9 transcription factors interferon regulatory factor 4 and PU.1. Systemically, IL-9 was abundantly produced by activated peripheral blood lymphocytes, whereas its receptor was overexpressed on gut resident and circulating PMN. IL-9 stimulation of the latter induced IL-8 production in a dose-dependent manner and rendered PMN resistant to apoptosis suggesting a functional role for IL-9R signalling in the propagation of gut inflammation. Furthermore, IL-9R was overexpressed on gut epithelial cells and IL-9 induced STAT5 activation in these cells. Moreover, IL-9 inhibited the growth of Caco-2 epithelial cell monolayers in wound healing experiments.
CONCLUSIONS: Our results provide evidence that IL-9 is predominantly involved in the pathogenesis of UC suggesting that targeting IL-9 might become a therapeutic option for patients with UC. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  IBD; Interleukins; Leukocytes; Ulcerative Colitis

Mesh:

Substances:

Year:  2014        PMID: 24957265     DOI: 10.1136/gutjnl-2013-305947

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  62 in total

Review 1.  Cytokine Networks and T-Cell Subsets in Inflammatory Bowel Diseases.

Authors:  Mei Lan Chen; Mark S Sundrud
Journal:  Inflamm Bowel Dis       Date:  2016-05       Impact factor: 5.325

2.  Altered STAT4 Isoform Expression in Patients with Inflammatory Bowel Disease.

Authors:  Rukhsana Jabeen; Lucy Miller; Weiguo Yao; Sandeep Gupta; Steven Steiner; Mark H Kaplan
Journal:  Inflamm Bowel Dis       Date:  2015-10       Impact factor: 5.325

Review 3.  The development and in vivo function of T helper 9 cells.

Authors:  Mark H Kaplan; Matthew M Hufford; Matthew R Olson
Journal:  Nat Rev Immunol       Date:  2015-04-07       Impact factor: 53.106

Review 4.  Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects.

Authors:  Mathurin Flamant; Josselin Rigaill; Stephane Paul; Xavier Roblin
Journal:  Drugs       Date:  2017-07       Impact factor: 9.546

5.  Stimulation of histamine H4 receptors increases the production of IL-9 in Th9 polarized cells.

Authors:  Katrin Schaper-Gerhardt; Mareike Wohlert; Susanne Mommert; Manfred Kietzmann; Thomas Werfel; Ralf Gutzmer
Journal:  Br J Pharmacol       Date:  2019-02-21       Impact factor: 8.739

6.  Increased IL-17A/IL-17F expression ratio represents the key mucosal T helper/regulatory cell-related gene signature paralleling disease activity in ulcerative colitis.

Authors:  Yoichiro Iboshi; Kazuhiko Nakamura; Keita Fukaura; Tsutomu Iwasa; Haruei Ogino; Yorinobu Sumida; Eikichi Ihara; Hirotada Akiho; Naohiko Harada; Makoto Nakamuta
Journal:  J Gastroenterol       Date:  2016-05-13       Impact factor: 7.527

Review 7.  TH9 cells in skin disorders.

Authors:  Rachael A Clark; Christoph Schlapbach
Journal:  Semin Immunopathol       Date:  2016-11-28       Impact factor: 9.623

Review 8.  JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

Authors:  Daniella M Schwartz; Yuka Kanno; Alejandro Villarino; Michael Ward; Massimo Gadina; John J O'Shea
Journal:  Nat Rev Drug Discov       Date:  2017-11-06       Impact factor: 84.694

9.  VEGF-C mediated enhancement of lymphatic drainage reduces intestinal inflammation by regulating IL-9/IL-17 balance and improving gut microbiota in experimental chronic colitis.

Authors:  Xiaolei Wang; Jin Zhao; Li Qin
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

10.  IL-9-producing Th9 cells may participate in pathogenesis of Takayasu's arteritis.

Authors:  Li-Li Pan; Juan Du; Na Gao; Hua Liao; Jin Wan; Wei-Ping Ci; Chun Yang; Tian Wang
Journal:  Clin Rheumatol       Date:  2016-09-15       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.